Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Piracetam for Treatment of Cocaine Addiction - 3

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Kyle Kampman, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000198
First received: September 20, 1999
Last updated: December 12, 2013
Last verified: December 2013
  Purpose

The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Piracetam
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Piracetam for Treatment of Cocaine Addiction

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Pulse, blood pressure
  • Adverse effects
  • High, anxiety, withdrawal

Estimated Enrollment: 0
Study Start Date: October 1996
Study Completion Date: October 1997
Primary Completion Date: October 1997 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000198

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: Kyle Kampman, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000198     History of Changes
Other Study ID Numbers: NIDA-00238-3, K20DA000238, K02-00238-3
Study First Received: September 20, 1999
Last Updated: December 12, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on November 25, 2014